Global Oligonucleotide Therapy-based Drug Market 2023 by Company, Regions, Type and Application, Forecast to 2029

November 2023 | 144 pages | ID: G8C94BECC008EN
GlobalInfoResearch

Abstracts

According to our (Global Info Research) latest study, the global Oligonucleotide Therapy-based Drug market size was valued at USD 65800 million in 2022 and is forecast to a readjusted size of USD 84010 million by 2029 with a CAGR of 3.6% during review period.

Oligonucleotides can be used to modulate gene expression via a range of processes including RNAi, target degradation by RNase H-mediated cleavage, splicing modulation, non-coding RNA inhibition, gene activation and programmed gene editing.

The Oligonucleotide Drug Delivery Market is driven by the rapid advancement in oligonucleotide-based therapies, including antisense, siRNA, and aptamer-based drugs, which hold immense potential for treating various genetic and rare diseases. These therapies rely on oligonucleotides to modulate gene expression, inhibit specific targets, or diagnose genetic disorders. As the understanding of genetic mechanisms and precision medicine continues to evolve, the demand for efficient and targeted delivery systems for oligonucleotide drugs grows. Innovations in drug delivery technologies, such as lipid nanoparticles and conjugates, as well as the expansion of oligonucleotide drug pipelines, further contribute to market expansion. However, a significant challenge for this market is the need to address the complexity of drug delivery, including overcoming biological barriers, minimizing off-target effects, and ensuring long-term safety and efficacy. Overcoming delivery hurdles, optimizing pharmacokinetics, and navigating regulatory pathways are ongoing challenges. Additionally, the market faces competition from traditional drug therapies, and the need for continuous research and development to enhance the delivery efficiency and patient acceptance of oligonucleotide drugs. Striking a balance between providing efficient and precise oligonucleotide drug delivery solutions while addressing safety and regulatory considerations is crucial for the continued growth of the Oligonucleotide Drug Delivery Market.

The Global Info Research report includes an overview of the development of the Oligonucleotide Therapy-based Drug industry chain, the market status of Neuromuscular Diseases (Antisense Oligonucleotides (ASO), siRNA), hATTR (Antisense Oligonucleotides (ASO), siRNA), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Oligonucleotide Therapy-based Drug.

Regionally, the report analyzes the Oligonucleotide Therapy-based Drug markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Oligonucleotide Therapy-based Drug market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:

The report presents comprehensive understanding of the Oligonucleotide Therapy-based Drug market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Oligonucleotide Therapy-based Drug industry.

The report involves analyzing the market at a macro level:

Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Antisense Oligonucleotides (ASO), siRNA).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Oligonucleotide Therapy-based Drug market.

Regional Analysis: The report involves examining the Oligonucleotide Therapy-based Drug market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Oligonucleotide Therapy-based Drug market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Oligonucleotide Therapy-based Drug:

Company Analysis: Report covers individual Oligonucleotide Therapy-based Drug players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Oligonucleotide Therapy-based Drug This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Neuromuscular Diseases, hATTR).

Technology Analysis: Report covers specific technologies relevant to Oligonucleotide Therapy-based Drug. It assesses the current state, advancements, and potential future developments in Oligonucleotide Therapy-based Drug areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Oligonucleotide Therapy-based Drug market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation

Oligonucleotide Therapy-based Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

Market segment by Type

• Antisense Oligonucleotides (ASO)
• siRNA
• mRNA

Market segment by Application

• Neuromuscular Diseases
• hATTR
• COVID-19
• Other

Market segment by players, this report covers

• Sarepta Therapeutics
• Ionis Pharmaceuticals
• Alnylam
• Biogen
• Nippon Shinyaku
• Sobi
• Novartis
• BioNTech
• Pfizer
• Moderna Therapeutics
• Jazz Pharmaceuticals
• CureVac
• Regulus Therapeutics
• ProQR
• Secarna
• MiNA Therapeutics
• Sylentis
• Arrowhead
• Silence Therapeutics
• Dicerna

Market segment by regions, regional analysis covers

• North America (United States, Canada, and Mexico)
• Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
• South America (Brazil, Argentina and Rest of South America)
• Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Oligonucleotide Therapy-based Drug product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Oligonucleotide Therapy-based Drug, with revenue, gross margin and global market share of Oligonucleotide Therapy-based Drug from 2018 to 2023.

Chapter 3, the Oligonucleotide Therapy-based Drug competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Oligonucleotide Therapy-based Drug market forecast, by regions, type and application, with consumption value, from 2024 to 2029.

Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Oligonucleotide Therapy-based Drug.

Chapter 13, to describe Oligonucleotide Therapy-based Drug research findings and conclusion.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope of Oligonucleotide Therapy-based Drug
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Oligonucleotide Therapy-based Drug by Type
  1.3.1 Overview: Global Oligonucleotide Therapy-based Drug Market Size by Type: 2018 Versus 2022 Versus 2029
  1.3.2 Global Oligonucleotide Therapy-based Drug Consumption Value Market Share by Type in 2022
  1.3.3 Antisense Oligonucleotides (ASO)
  1.3.4 siRNA
  1.3.5 mRNA
1.4 Global Oligonucleotide Therapy-based Drug Market by Application
  1.4.1 Overview: Global Oligonucleotide Therapy-based Drug Market Size by Application: 2018 Versus 2022 Versus 2029
  1.4.2 Neuromuscular Diseases
  1.4.3 hATTR
  1.4.4 COVID-19
  1.4.5 Other
1.5 Global Oligonucleotide Therapy-based Drug Market Size & Forecast
1.6 Global Oligonucleotide Therapy-based Drug Market Size and Forecast by Region
  1.6.1 Global Oligonucleotide Therapy-based Drug Market Size by Region: 2018 VS 2022 VS 2029
  1.6.2 Global Oligonucleotide Therapy-based Drug Market Size by Region, (2018-2029)
  1.6.3 North America Oligonucleotide Therapy-based Drug Market Size and Prospect (2018-2029)
  1.6.4 Europe Oligonucleotide Therapy-based Drug Market Size and Prospect (2018-2029)
  1.6.5 Asia-Pacific Oligonucleotide Therapy-based Drug Market Size and Prospect (2018-2029)
  1.6.6 South America Oligonucleotide Therapy-based Drug Market Size and Prospect (2018-2029)
  1.6.7 Middle East and Africa Oligonucleotide Therapy-based Drug Market Size and Prospect (2018-2029)

2 COMPANY PROFILES

2.1 Sarepta Therapeutics
  2.1.1 Sarepta Therapeutics Details
  2.1.2 Sarepta Therapeutics Major Business
  2.1.3 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product and Solutions
  2.1.4 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
  2.1.5 Sarepta Therapeutics Recent Developments and Future Plans
2.2 Ionis Pharmaceuticals
  2.2.1 Ionis Pharmaceuticals Details
  2.2.2 Ionis Pharmaceuticals Major Business
  2.2.3 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product and Solutions
  2.2.4 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
  2.2.5 Ionis Pharmaceuticals Recent Developments and Future Plans
2.3 Alnylam
  2.3.1 Alnylam Details
  2.3.2 Alnylam Major Business
  2.3.3 Alnylam Oligonucleotide Therapy-based Drug Product and Solutions
  2.3.4 Alnylam Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
  2.3.5 Alnylam Recent Developments and Future Plans
2.4 Biogen
  2.4.1 Biogen Details
  2.4.2 Biogen Major Business
  2.4.3 Biogen Oligonucleotide Therapy-based Drug Product and Solutions
  2.4.4 Biogen Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
  2.4.5 Biogen Recent Developments and Future Plans
2.5 Nippon Shinyaku
  2.5.1 Nippon Shinyaku Details
  2.5.2 Nippon Shinyaku Major Business
  2.5.3 Nippon Shinyaku Oligonucleotide Therapy-based Drug Product and Solutions
  2.5.4 Nippon Shinyaku Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
  2.5.5 Nippon Shinyaku Recent Developments and Future Plans
2.6 Sobi
  2.6.1 Sobi Details
  2.6.2 Sobi Major Business
  2.6.3 Sobi Oligonucleotide Therapy-based Drug Product and Solutions
  2.6.4 Sobi Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
  2.6.5 Sobi Recent Developments and Future Plans
2.7 Novartis
  2.7.1 Novartis Details
  2.7.2 Novartis Major Business
  2.7.3 Novartis Oligonucleotide Therapy-based Drug Product and Solutions
  2.7.4 Novartis Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
  2.7.5 Novartis Recent Developments and Future Plans
2.8 BioNTech
  2.8.1 BioNTech Details
  2.8.2 BioNTech Major Business
  2.8.3 BioNTech Oligonucleotide Therapy-based Drug Product and Solutions
  2.8.4 BioNTech Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
  2.8.5 BioNTech Recent Developments and Future Plans
2.9 Pfizer
  2.9.1 Pfizer Details
  2.9.2 Pfizer Major Business
  2.9.3 Pfizer Oligonucleotide Therapy-based Drug Product and Solutions
  2.9.4 Pfizer Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
  2.9.5 Pfizer Recent Developments and Future Plans
2.10 Moderna Therapeutics
  2.10.1 Moderna Therapeutics Details
  2.10.2 Moderna Therapeutics Major Business
  2.10.3 Moderna Therapeutics Oligonucleotide Therapy-based Drug Product and Solutions
  2.10.4 Moderna Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
  2.10.5 Moderna Therapeutics Recent Developments and Future Plans
2.11 Jazz Pharmaceuticals
  2.11.1 Jazz Pharmaceuticals Details
  2.11.2 Jazz Pharmaceuticals Major Business
  2.11.3 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product and Solutions
  2.11.4 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
  2.11.5 Jazz Pharmaceuticals Recent Developments and Future Plans
2.12 CureVac
  2.12.1 CureVac Details
  2.12.2 CureVac Major Business
  2.12.3 CureVac Oligonucleotide Therapy-based Drug Product and Solutions
  2.12.4 CureVac Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
  2.12.5 CureVac Recent Developments and Future Plans
2.13 Regulus Therapeutics
  2.13.1 Regulus Therapeutics Details
  2.13.2 Regulus Therapeutics Major Business
  2.13.3 Regulus Therapeutics Oligonucleotide Therapy-based Drug Product and Solutions
  2.13.4 Regulus Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
  2.13.5 Regulus Therapeutics Recent Developments and Future Plans
2.14 ProQR
  2.14.1 ProQR Details
  2.14.2 ProQR Major Business
  2.14.3 ProQR Oligonucleotide Therapy-based Drug Product and Solutions
  2.14.4 ProQR Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
  2.14.5 ProQR Recent Developments and Future Plans
2.15 Secarna
  2.15.1 Secarna Details
  2.15.2 Secarna Major Business
  2.15.3 Secarna Oligonucleotide Therapy-based Drug Product and Solutions
  2.15.4 Secarna Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
  2.15.5 Secarna Recent Developments and Future Plans
2.16 MiNA Therapeutics
  2.16.1 MiNA Therapeutics Details
  2.16.2 MiNA Therapeutics Major Business
  2.16.3 MiNA Therapeutics Oligonucleotide Therapy-based Drug Product and Solutions
  2.16.4 MiNA Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
  2.16.5 MiNA Therapeutics Recent Developments and Future Plans
2.17 Sylentis
  2.17.1 Sylentis Details
  2.17.2 Sylentis Major Business
  2.17.3 Sylentis Oligonucleotide Therapy-based Drug Product and Solutions
  2.17.4 Sylentis Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
  2.17.5 Sylentis Recent Developments and Future Plans
2.18 Arrowhead
  2.18.1 Arrowhead Details
  2.18.2 Arrowhead Major Business
  2.18.3 Arrowhead Oligonucleotide Therapy-based Drug Product and Solutions
  2.18.4 Arrowhead Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
  2.18.5 Arrowhead Recent Developments and Future Plans
2.19 Silence Therapeutics
  2.19.1 Silence Therapeutics Details
  2.19.2 Silence Therapeutics Major Business
  2.19.3 Silence Therapeutics Oligonucleotide Therapy-based Drug Product and Solutions
  2.19.4 Silence Therapeutics Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
  2.19.5 Silence Therapeutics Recent Developments and Future Plans
2.20 Dicerna
  2.20.1 Dicerna Details
  2.20.2 Dicerna Major Business
  2.20.3 Dicerna Oligonucleotide Therapy-based Drug Product and Solutions
  2.20.4 Dicerna Oligonucleotide Therapy-based Drug Revenue, Gross Margin and Market Share (2018-2023)
  2.20.5 Dicerna Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

3.1 Global Oligonucleotide Therapy-based Drug Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
  3.2.1 Market Share of Oligonucleotide Therapy-based Drug by Company Revenue
  3.2.2 Top 3 Oligonucleotide Therapy-based Drug Players Market Share in 2022
  3.2.3 Top 6 Oligonucleotide Therapy-based Drug Players Market Share in 2022
3.3 Oligonucleotide Therapy-based Drug Market: Overall Company Footprint Analysis
  3.3.1 Oligonucleotide Therapy-based Drug Market: Region Footprint
  3.3.2 Oligonucleotide Therapy-based Drug Market: Company Product Type Footprint
  3.3.3 Oligonucleotide Therapy-based Drug Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations

4 MARKET SIZE SEGMENT BY TYPE

4.1 Global Oligonucleotide Therapy-based Drug Consumption Value and Market Share by Type (2018-2023)
4.2 Global Oligonucleotide Therapy-based Drug Market Forecast by Type (2024-2029)

5 MARKET SIZE SEGMENT BY APPLICATION

5.1 Global Oligonucleotide Therapy-based Drug Consumption Value Market Share by Application (2018-2023)
5.2 Global Oligonucleotide Therapy-based Drug Market Forecast by Application (2024-2029)

6 NORTH AMERICA

6.1 North America Oligonucleotide Therapy-based Drug Consumption Value by Type (2018-2029)
6.2 North America Oligonucleotide Therapy-based Drug Consumption Value by Application (2018-2029)
6.3 North America Oligonucleotide Therapy-based Drug Market Size by Country
  6.3.1 North America Oligonucleotide Therapy-based Drug Consumption Value by Country (2018-2029)
  6.3.2 United States Oligonucleotide Therapy-based Drug Market Size and Forecast (2018-2029)
  6.3.3 Canada Oligonucleotide Therapy-based Drug Market Size and Forecast (2018-2029)
  6.3.4 Mexico Oligonucleotide Therapy-based Drug Market Size and Forecast (2018-2029)

7 EUROPE

7.1 Europe Oligonucleotide Therapy-based Drug Consumption Value by Type (2018-2029)
7.2 Europe Oligonucleotide Therapy-based Drug Consumption Value by Application (2018-2029)
7.3 Europe Oligonucleotide Therapy-based Drug Market Size by Country
  7.3.1 Europe Oligonucleotide Therapy-based Drug Consumption Value by Country (2018-2029)
  7.3.2 Germany Oligonucleotide Therapy-based Drug Market Size and Forecast (2018-2029)
  7.3.3 France Oligonucleotide Therapy-based Drug Market Size and Forecast (2018-2029)
  7.3.4 United Kingdom Oligonucleotide Therapy-based Drug Market Size and Forecast (2018-2029)
  7.3.5 Russia Oligonucleotide Therapy-based Drug Market Size and Forecast (2018-2029)
  7.3.6 Italy Oligonucleotide Therapy-based Drug Market Size and Forecast (2018-2029)

8 ASIA-PACIFIC

8.1 Asia-Pacific Oligonucleotide Therapy-based Drug Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Oligonucleotide Therapy-based Drug Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Oligonucleotide Therapy-based Drug Market Size by Region
  8.3.1 Asia-Pacific Oligonucleotide Therapy-based Drug Consumption Value by Region (2018-2029)
  8.3.2 China Oligonucleotide Therapy-based Drug Market Size and Forecast (2018-2029)
  8.3.3 Japan Oligonucleotide Therapy-based Drug Market Size and Forecast (2018-2029)
  8.3.4 South Korea Oligonucleotide Therapy-based Drug Market Size and Forecast (2018-2029)
  8.3.5 India Oligonucleotide Therapy-based Drug Market Size and Forecast (2018-2029)
  8.3.6 Southeast Asia Oligonucleotide Therapy-based Drug Market Size and Forecast (2018-2029)
  8.3.7 Australia Oligonucleotide Therapy-based Drug Market Size and Forecast (2018-2029)

9 SOUTH AMERICA

9.1 South America Oligonucleotide Therapy-based Drug Consumption Value by Type (2018-2029)
9.2 South America Oligonucleotide Therapy-based Drug Consumption Value by Application (2018-2029)
9.3 South America Oligonucleotide Therapy-based Drug Market Size by Country
  9.3.1 South America Oligonucleotide Therapy-based Drug Consumption Value by Country (2018-2029)
  9.3.2 Brazil Oligonucleotide Therapy-based Drug Market Size and Forecast (2018-2029)
  9.3.3 Argentina Oligonucleotide Therapy-based Drug Market Size and Forecast (2018-2029)

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Oligonucleotide Therapy-based Drug Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Oligonucleotide Therapy-based Drug Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Country
  10.3.1 Middle East & Africa Oligonucleotide Therapy-based Drug Consumption Value by Country (2018-2029)
  10.3.2 Turkey Oligonucleotide Therapy-based Drug Market Size and Forecast (2018-2029)
  10.3.3 Saudi Arabia Oligonucleotide Therapy-based Drug Market Size and Forecast (2018-2029)
  10.3.4 UAE Oligonucleotide Therapy-based Drug Market Size and Forecast (2018-2029)

11 MARKET DYNAMICS

11.1 Oligonucleotide Therapy-based Drug Market Drivers
11.2 Oligonucleotide Therapy-based Drug Market Restraints
11.3 Oligonucleotide Therapy-based Drug Trends Analysis
11.4 Porters Five Forces Analysis
  11.4.1 Threat of New Entrants
  11.4.2 Bargaining Power of Suppliers
  11.4.3 Bargaining Power of Buyers
  11.4.4 Threat of Substitutes
  11.4.5 Competitive Rivalry

12 INDUSTRY CHAIN ANALYSIS

12.1 Oligonucleotide Therapy-based Drug Industry Chain
12.2 Oligonucleotide Therapy-based Drug Upstream Analysis
12.3 Oligonucleotide Therapy-based Drug Midstream Analysis
12.4 Oligonucleotide Therapy-based Drug Downstream Analysis

13 RESEARCH FINDINGS AND CONCLUSION


14 APPENDIX

14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Oligonucleotide Therapy-based Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Oligonucleotide Therapy-based Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Oligonucleotide Therapy-based Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Oligonucleotide Therapy-based Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Sarepta Therapeutics Company Information, Head Office, and Major Competitors
Table 6. Sarepta Therapeutics Major Business
Table 7. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product and Solutions
Table 8. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Sarepta Therapeutics Recent Developments and Future Plans
Table 10. Ionis Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 11. Ionis Pharmaceuticals Major Business
Table 12. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product and Solutions
Table 13. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Ionis Pharmaceuticals Recent Developments and Future Plans
Table 15. Alnylam Company Information, Head Office, and Major Competitors
Table 16. Alnylam Major Business
Table 17. Alnylam Oligonucleotide Therapy-based Drug Product and Solutions
Table 18. Alnylam Oligonucleotide Therapy-based Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Alnylam Recent Developments and Future Plans
Table 20. Biogen Company Information, Head Office, and Major Competitors
Table 21. Biogen Major Business
Table 22. Biogen Oligonucleotide Therapy-based Drug Product and Solutions
Table 23. Biogen Oligonucleotide Therapy-based Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Biogen Recent Developments and Future Plans
Table 25. Nippon Shinyaku Company Information, Head Office, and Major Competitors
Table 26. Nippon Shinyaku Major Business
Table 27. Nippon Shinyaku Oligonucleotide Therapy-based Drug Product and Solutions
Table 28. Nippon Shinyaku Oligonucleotide Therapy-based Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Nippon Shinyaku Recent Developments and Future Plans
Table 30. Sobi Company Information, Head Office, and Major Competitors
Table 31. Sobi Major Business
Table 32. Sobi Oligonucleotide Therapy-based Drug Product and Solutions
Table 33. Sobi Oligonucleotide Therapy-based Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Sobi Recent Developments and Future Plans
Table 35. Novartis Company Information, Head Office, and Major Competitors
Table 36. Novartis Major Business
Table 37. Novartis Oligonucleotide Therapy-based Drug Product and Solutions
Table 38. Novartis Oligonucleotide Therapy-based Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Novartis Recent Developments and Future Plans
Table 40. BioNTech Company Information, Head Office, and Major Competitors
Table 41. BioNTech Major Business
Table 42. BioNTech Oligonucleotide Therapy-based Drug Product and Solutions
Table 43. BioNTech Oligonucleotide Therapy-based Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. BioNTech Recent Developments and Future Plans
Table 45. Pfizer Company Information, Head Office, and Major Competitors
Table 46. Pfizer Major Business
Table 47. Pfizer Oligonucleotide Therapy-based Drug Product and Solutions
Table 48. Pfizer Oligonucleotide Therapy-based Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Pfizer Recent Developments and Future Plans
Table 50. Moderna Therapeutics Company Information, Head Office, and Major Competitors
Table 51. Moderna Therapeutics Major Business
Table 52. Moderna Therapeutics Oligonucleotide Therapy-based Drug Product and Solutions
Table 53. Moderna Therapeutics Oligonucleotide Therapy-based Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Moderna Therapeutics Recent Developments and Future Plans
Table 55. Jazz Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 56. Jazz Pharmaceuticals Major Business
Table 57. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product and Solutions
Table 58. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Jazz Pharmaceuticals Recent Developments and Future Plans
Table 60. CureVac Company Information, Head Office, and Major Competitors
Table 61. CureVac Major Business
Table 62. CureVac Oligonucleotide Therapy-based Drug Product and Solutions
Table 63. CureVac Oligonucleotide Therapy-based Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. CureVac Recent Developments and Future Plans
Table 65. Regulus Therapeutics Company Information, Head Office, and Major Competitors
Table 66. Regulus Therapeutics Major Business
Table 67. Regulus Therapeutics Oligonucleotide Therapy-based Drug Product and Solutions
Table 68. Regulus Therapeutics Oligonucleotide Therapy-based Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. Regulus Therapeutics Recent Developments and Future Plans
Table 70. ProQR Company Information, Head Office, and Major Competitors
Table 71. ProQR Major Business
Table 72. ProQR Oligonucleotide Therapy-based Drug Product and Solutions
Table 73. ProQR Oligonucleotide Therapy-based Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. ProQR Recent Developments and Future Plans
Table 75. Secarna Company Information, Head Office, and Major Competitors
Table 76. Secarna Major Business
Table 77. Secarna Oligonucleotide Therapy-based Drug Product and Solutions
Table 78. Secarna Oligonucleotide Therapy-based Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. Secarna Recent Developments and Future Plans
Table 80. MiNA Therapeutics Company Information, Head Office, and Major Competitors
Table 81. MiNA Therapeutics Major Business
Table 82. MiNA Therapeutics Oligonucleotide Therapy-based Drug Product and Solutions
Table 83. MiNA Therapeutics Oligonucleotide Therapy-based Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 84. MiNA Therapeutics Recent Developments and Future Plans
Table 85. Sylentis Company Information, Head Office, and Major Competitors
Table 86. Sylentis Major Business
Table 87. Sylentis Oligonucleotide Therapy-based Drug Product and Solutions
Table 88. Sylentis Oligonucleotide Therapy-based Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Sylentis Recent Developments and Future Plans
Table 90. Arrowhead Company Information, Head Office, and Major Competitors
Table 91. Arrowhead Major Business
Table 92. Arrowhead Oligonucleotide Therapy-based Drug Product and Solutions
Table 93. Arrowhead Oligonucleotide Therapy-based Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 94. Arrowhead Recent Developments and Future Plans
Table 95. Silence Therapeutics Company Information, Head Office, and Major Competitors
Table 96. Silence Therapeutics Major Business
Table 97. Silence Therapeutics Oligonucleotide Therapy-based Drug Product and Solutions
Table 98. Silence Therapeutics Oligonucleotide Therapy-based Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 99. Silence Therapeutics Recent Developments and Future Plans
Table 100. Dicerna Company Information, Head Office, and Major Competitors
Table 101. Dicerna Major Business
Table 102. Dicerna Oligonucleotide Therapy-based Drug Product and Solutions
Table 103. Dicerna Oligonucleotide Therapy-based Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 104. Dicerna Recent Developments and Future Plans
Table 105. Global Oligonucleotide Therapy-based Drug Revenue (USD Million) by Players (2018-2023)
Table 106. Global Oligonucleotide Therapy-based Drug Revenue Share by Players (2018-2023)
Table 107. Breakdown of Oligonucleotide Therapy-based Drug by Company Type (Tier 1, Tier 2, and Tier 3)
Table 108. Market Position of Players in Oligonucleotide Therapy-based Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 109. Head Office of Key Oligonucleotide Therapy-based Drug Players
Table 110. Oligonucleotide Therapy-based Drug Market: Company Product Type Footprint
Table 111. Oligonucleotide Therapy-based Drug Market: Company Product Application Footprint
Table 112. Oligonucleotide Therapy-based Drug New Market Entrants and Barriers to Market Entry
Table 113. Oligonucleotide Therapy-based Drug Mergers, Acquisition, Agreements, and Collaborations
Table 114. Global Oligonucleotide Therapy-based Drug Consumption Value (USD Million) by Type (2018-2023)
Table 115. Global Oligonucleotide Therapy-based Drug Consumption Value Share by Type (2018-2023)
Table 116. Global Oligonucleotide Therapy-based Drug Consumption Value Forecast by Type (2024-2029)
Table 117. Global Oligonucleotide Therapy-based Drug Consumption Value by Application (2018-2023)
Table 118. Global Oligonucleotide Therapy-based Drug Consumption Value Forecast by Application (2024-2029)
Table 119. North America Oligonucleotide Therapy-based Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 120. North America Oligonucleotide Therapy-based Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 121. North America Oligonucleotide Therapy-based Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 122. North America Oligonucleotide Therapy-based Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 123. North America Oligonucleotide Therapy-based Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 124. North America Oligonucleotide Therapy-based Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 125. Europe Oligonucleotide Therapy-based Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 126. Europe Oligonucleotide Therapy-based Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 127. Europe Oligonucleotide Therapy-based Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 128. Europe Oligonucleotide Therapy-based Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 129. Europe Oligonucleotide Therapy-based Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 130. Europe Oligonucleotide Therapy-based Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 131. Asia-Pacific Oligonucleotide Therapy-based Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 132. Asia-Pacific Oligonucleotide Therapy-based Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 133. Asia-Pacific Oligonucleotide Therapy-based Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 134. Asia-Pacific Oligonucleotide Therapy-based Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 135. Asia-Pacific Oligonucleotide Therapy-based Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 136. Asia-Pacific Oligonucleotide Therapy-based Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 137. South America Oligonucleotide Therapy-based Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 138. South America Oligonucleotide Therapy-based Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 139. South America Oligonucleotide Therapy-based Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 140. South America Oligonucleotide Therapy-based Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 141. South America Oligonucleotide Therapy-based Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 142. South America Oligonucleotide Therapy-based Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 143. Middle East & Africa Oligonucleotide Therapy-based Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 144. Middle East & Africa Oligonucleotide Therapy-based Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 145. Middle East & Africa Oligonucleotide Therapy-based Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 146. Middle East & Africa Oligonucleotide Therapy-based Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 147. Middle East & Africa Oligonucleotide Therapy-based Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 148. Middle East & Africa Oligonucleotide Therapy-based Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 149. Oligonucleotide Therapy-based Drug Raw Material
Table 150. Key Suppliers of Oligonucleotide Therapy-based Drug Raw Materials

List Of Figures

LIST OF FIGURES

Figure 1. Oligonucleotide Therapy-based Drug Picture
Figure 2. Global Oligonucleotide Therapy-based Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Oligonucleotide Therapy-based Drug Consumption Value Market Share by Type in 2022
Figure 4. Antisense Oligonucleotides (ASO)
Figure 5. siRNA
Figure 6. mRNA
Figure 7. Global Oligonucleotide Therapy-based Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 8. Oligonucleotide Therapy-based Drug Consumption Value Market Share by Application in 2022
Figure 9. Neuromuscular Diseases Picture
Figure 10. hATTR Picture
Figure 11. COVID-19 Picture
Figure 12. Other Picture
Figure 13. Global Oligonucleotide Therapy-based Drug Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Oligonucleotide Therapy-based Drug Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Market Oligonucleotide Therapy-based Drug Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 16. Global Oligonucleotide Therapy-based Drug Consumption Value Market Share by Region (2018-2029)
Figure 17. Global Oligonucleotide Therapy-based Drug Consumption Value Market Share by Region in 2022
Figure 18. North America Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 20. Asia-Pacific Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 21. South America Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 22. Middle East and Africa Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 23. Global Oligonucleotide Therapy-based Drug Revenue Share by Players in 2022
Figure 24. Oligonucleotide Therapy-based Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 25. Global Top 3 Players Oligonucleotide Therapy-based Drug Market Share in 2022
Figure 26. Global Top 6 Players Oligonucleotide Therapy-based Drug Market Share in 2022
Figure 27. Global Oligonucleotide Therapy-based Drug Consumption Value Share by Type (2018-2023)
Figure 28. Global Oligonucleotide Therapy-based Drug Market Share Forecast by Type (2024-2029)
Figure 29. Global Oligonucleotide Therapy-based Drug Consumption Value Share by Application (2018-2023)
Figure 30. Global Oligonucleotide Therapy-based Drug Market Share Forecast by Application (2024-2029)
Figure 31. North America Oligonucleotide Therapy-based Drug Consumption Value Market Share by Type (2018-2029)
Figure 32. North America Oligonucleotide Therapy-based Drug Consumption Value Market Share by Application (2018-2029)
Figure 33. North America Oligonucleotide Therapy-based Drug Consumption Value Market Share by Country (2018-2029)
Figure 34. United States Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 35. Canada Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 36. Mexico Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 37. Europe Oligonucleotide Therapy-based Drug Consumption Value Market Share by Type (2018-2029)
Figure 38. Europe Oligonucleotide Therapy-based Drug Consumption Value Market Share by Application (2018-2029)
Figure 39. Europe Oligonucleotide Therapy-based Drug Consumption Value Market Share by Country (2018-2029)
Figure 40. Germany Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 41. France Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 42. United Kingdom Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 43. Russia Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 44. Italy Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 45. Asia-Pacific Oligonucleotide Therapy-based Drug Consumption Value Market Share by Type (2018-2029)
Figure 46. Asia-Pacific Oligonucleotide Therapy-based Drug Consumption Value Market Share by Application (2018-2029)
Figure 47. Asia-Pacific Oligonucleotide Therapy-based Drug Consumption Value Market Share by Region (2018-2029)
Figure 48. China Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 49. Japan Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 50. South Korea Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 51. India Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 52. Southeast Asia Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 53. Australia Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 54. South America Oligonucleotide Therapy-based Drug Consumption Value Market Share by Type (2018-2029)
Figure 55. South America Oligonucleotide Therapy-based Drug Consumption Value Market Share by Application (2018-2029)
Figure 56. South America Oligonucleotide Therapy-based Drug Consumption Value Market Share by Country (2018-2029)
Figure 57. Brazil Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 58. Argentina Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 59. Middle East and Africa Oligonucleotide Therapy-based Drug Consumption Value Market Share by Type (2018-2029)
Figure 60. Middle East and Africa Oligonucleotide Therapy-based Drug Consumption Value Market Share by Application (2018-2029)
Figure 61. Middle East and Africa Oligonucleotide Therapy-based Drug Consumption Value Market Share by Country (2018-2029)
Figure 62. Turkey Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 63. Saudi Arabia Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 64. UAE Oligonucleotide Therapy-based Drug Consumption Value (2018-2029) & (USD Million)
Figure 65. Oligonucleotide Therapy-based Drug Market Drivers
Figure 66. Oligonucleotide Therapy-based Drug Market Restraints
Figure 67. Oligonucleotide Therapy-based Drug Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Manufacturing Cost Structure Analysis of Oligonucleotide Therapy-based Drug in 2022
Figure 70. Manufacturing Process Analysis of Oligonucleotide Therapy-based Drug
Figure 71. Oligonucleotide Therapy-based Drug Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source